磁共振颈动脉斑块成像用于加拿大卒中一级预防的成本效果
本研究通过TreeAge Pro成本效果模拟,比较一线颈动脉多普勒超声(DUS)常规随访与一线MR评估狭窄及斑块内出血(MRIPH)两种策略用于狭窄<50%的高危患者。70岁患者中,MRIPH策略使卒中相对风险降低16.8%(每患者终生0.080 vs 0.097次卒中),质量调整生命年增加(12.23 vs 12.20),终生平均总费用增加897.33加元(5784.53 vs 4887.20加元),增量成本效果比为每质量调整生命年29,744加元。作者认为MRIPH是识别需年度监测和及时处理的无症状卒中高危患者的成本效果一线工具。
要点
- 对狭窄<50%的高危患者,一线MRIPH策略较DUS使卒中相对风险降低16.8%(0.080 vs 0.097次/患者终生)。
- MRIPH策略质量调整生命年12.23 vs DUS 12.20,终生平均总费用5784.53 vs 4887.20加元。
- 增量成本效果比为每质量调整生命年29,744加元,在50,000加元支付意愿阈值下91.8%的敏感性分析中保持成本效果。
核心结论
- 作者认为MRIPH是成本效果良好的一线工具,用于识别需要年度监测和及时处理的无症状卒中高危患者。
研究设计与样本
- 成本效果模拟研究,使用TreeAge Pro比较一线DUS常规随访与一线MR评估狭窄及斑块内出血(MRIPH)两种策略,对象为狭窄<50%的高危患者。
诊断标准与关键数值
- MRIPH策略中,存在斑块内出血(IPH)的患者接受年度DUS监测,若斑块进展则立即行颈动脉内膜切除术。
- 70岁患者中,MRIPH策略卒中相对风险降低16.8%(每患者终生0.080 vs 0.097次卒中)。
- 增量成本效果比为每质量调整生命年29,744加元,在50,000加元支付意愿阈值下91.8%的敏感性分析中保持成本效果。
临床应用与阅片要点
- 作者认为MRIPH可作为一线工具识别需要年度监测和及时处理的无症状卒中高危患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Magnetic resonance of the carotid arteries provides important insight into plaque composition and vulnerability in addition to the traditional measure of stenosis. The purpose of this study was to evaluate the cost-effectiveness of MR imaging as a first-line modality to assess carotid disease and guide management for high-risk patients with <50% stenosis.
METHODS: Using TreeAge Pro, a cost-effectiveness simulation was conducted comparing two strategies: (a) standard of care first-line carotid duplex ultrasound (DUS) with regular follow-up, vs (b) first-line MR assessment of stenosis and intraplaque haemorrhage (MRIPH) in which patients with IPH received annual DUS surveillance and immediate carotid endarterectomy in case of plaque progression.
RESULTS: For patients aged 70 years old, using a first-line MRIPH strategy resulted in a 16.8% relative risk reduction in strokes compared to DUS (0.080 vs 0.097 strokes per patient per lifetime), and an increased quality-adjusted-life years (12.23 vs 12.20) at an increased cost of $897.33 over a patient's lifetime ($5784.53 vs $4887.20 average total cost per patient per lifetime). The incremental cost-effectiveness ratio was $29,744 per quality-adjusted-life years. MRIPH remained cost-effective below a willingness-to-pay threshold of $50,000 for 91.8% of sensitivity analyses.
CONCLUSION: MRIPH was found to be a cost-effective first-line tool to identify asymptomatic patients at high risk for stroke requiring annual surveillance and prompt management. Advances in Knowledge: Using MR imaging as a fist-line method to detect the presence of IPH provides clinically useful and cost-effective information that allows for enhanced risk evaluation and primary stroke prevention.
引用
- Lechtman E, Balki I, Thomas K, et al. Cost-effectiveness of magnetic resonance carotid plaque imaging for primary stroke prevention in Canada. Br J Radiol. 2017. PMID: 29076745. doi:10.1259/bjr.20170518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。